The text starts here.

News Release

FOR IMMEDIATE RELEASE
September 14, 2011

SUPREME COURT OF JAPAN RULES TO EXTEND EISAI'S PATENT FOR
ARICEPT® IN RELATION TO SEVERE ALZHEIMER'S DISEASE

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that the Supreme Court of Japan has turned down a petition filed by generic drug manufacturers in regards to an Intellectual Property High Court ruling to maintain a decision to grant an extension for the Aricept® (donepezil hydrochloride) patent in relation to severe Alzheimer's disease.

On February 22, 2011, the Intellectual Property High Court of Japan ruled in a trial to maintain the decision made by the Japan Patent Office to maintain the patent term extension, which would effectively see the patent term for Aricept® in relation to severe Alzheimer's disease be extended until June 22, 2013.

In response to this ruling by the Intellectual Property High Court of Japan, a number of generic drug manufacturers filed a petition dated March 8, 2011, however, on September 9, 2011, the Supreme Court handed down its decision to turn down this request for an appeal hearing. As a result of this decision, the term of the Aricept® patent in relation to severe Alzheimer's disease was extended to June 22, 2013.

Aricept® is the only drug in Japan to be approved for all stages of Alzheimer's diseaseļ¼mild to severe. Eisai remains committed to making further contributions to increase the benefits provided to an even greater number of Alzheimer's patients, their families and caregivers.


Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120